Awaiting results
V940-001 — intismeran autogene + pembrolizumab (high-risk melanoma, phase III)
A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-risk Stage II-IV Melanoma
- Phase
- Phase III
- Recruitment
- Active, not recruiting
- Results maturity
- No results
- Publication
- No publication
- Regulatory approval
- No regulatory approval
- NCT
- NCT05933577
- Registry checked
- 2026-10-29
- Editorial update
- 2026-10-29
Not a treatment recommendation. Experimental or ongoing research does not by itself replace standard care.
For patients
What is being studied? A large phase III trial is testing personalized mRNA vaccine plus immunotherapy after surgery in high-risk melanoma.
Why promising? Tests personalized mRNA + PD-1 adjuvant strategy in randomized phase III.
What is not proven? No primary results yet; KEYNOTE-942 alone is not phase III confirmation.
Is this standard care today? This listing alone does not replace standard care; approval and guideline context require clinician judgment.
For clinicians
Phase III; enrollment closed. Read maturity from primary publication.
Cancer / population: Melanoma — Yüksek risk evre II–IV melanom (protokol)
Intervention: Adjuvan V940 (mRNA-4157) + pembrolizumab
Primary endpoint: RFS (protokol)
Limitations: Sonuç bekleniyor; üretim/lojistik genellenebilirlik ayrı konu.